Zeltia Soars After Agreement With Janssen on Yondelis for U.S.
This article is for subscribers only.
Zeltia SA, which develops cancer drugs from sea creatures, gained the most in more than two months after an agreement with Johnson & Johnson on how to pursue the U.S. development of its cancer medicine Yondelis.
Zeltia rose as much as 13 percent to 1.63 euros, the biggest intraday gain since Oct. 25, and was up 10 percent at 1:38 p.m. in Madrid.